Maxim Group analyst Jason Kolbert weighed in on Inovio Pharmaceuticals (NYSE: INO) ahead of what he called a "binary event.""We ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE